Lidds Ab (publ)Company Review & Valuation

LIDDS
Nasdaq First North Growth Market
Latest Price
13.05SEK
Market Capitalization
316.53mSEK

About Lidds Ab (publ)

LIDDS AB (publ) develops and sells pharmaceutical products for cancer and other diseases worldwide. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX for lung cancer and solid tumors; NZ-DOX for solid tumors; NZ-IO, an antibody-based immunotherapy; NZ-STING for immuno-Show moreoncology; and NZ-BELINA for breast cancer. The company is based in Uppsala, Sweden.Show less

Industry
Biotechnology
HQ Location
Uppsala, Sweden

Stock Price

Price data not available for Lidds Ab (publ).

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

Celgene
Advaxis, Inc.
NovaBay Pharmaceuticals
AquaBounty Technologies

back to top